Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Lediane Moreira Lopes"'
Autor:
Markus Bredemeier, Lediane Moreira Lopes, Matheus Augusto Eisenreich, Sheila Hickmann, Guilherme Kopik Bongiorno, Rui d’Avila, André Luis Bittencourt Morsch, Fernando da Silva Stein, Guilherme Gomes Dias Campos
Publikováno v:
BMC Cardiovascular Disorders, Vol 18, Iss 1, Pp 1-11 (2018)
Abstract Background Xanthine oxidase inhibitors (XOI), classified as purine-like (allopurinol and oxypurinol) and non-purine (febuxostat and topiroxostat) XOI, present antioxidant properties by reducing the production of reactive oxygen species deriv
Externí odkaz:
https://doaj.org/article/6a32f944013549cbbbc53749bc3487fb
Autor:
Rui d’Avila, Guilherme Kopik Bongiorno, Fernando da Silva Stein, Sheila Hickmann, Lediane Moreira Lopes, Markus Bredemeier, Matheus Augusto Eisenreich, Guilherme Gomes Dias Campos, André Luis Bittencourt Morsch
Publikováno v:
BMC Cardiovascular Disorders, Vol 18, Iss 1, Pp 1-11 (2018)
BMC Cardiovascular Disorders
BMC Cardiovascular Disorders
Background Xanthine oxidase inhibitors (XOI), classified as purine-like (allopurinol and oxypurinol) and non-purine (febuxostat and topiroxostat) XOI, present antioxidant properties by reducing the production of reactive oxygen species derived from p
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d6467b99c081df59c5563b6922482b58
http://link.springer.com/article/10.1186/s12872-018-0757-9
http://link.springer.com/article/10.1186/s12872-018-0757-9
Autor:
Lediane Moreira Lopes, Matheus Augusto Eisenreich, Markus Bredemeier, Aline Defaveri do Prado, Guilherme Gomes Dias Campos
Publikováno v:
Annals of Dermatology
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7aaf36aa4a0a35826d0d1743a57b9237
http://europepmc.org/articles/PMC5318515
http://europepmc.org/articles/PMC5318515
Autor:
Markus Bredemeier, Guilherme Kopik Bongiorno, Lediane Moreira Lopes, Sheila Hickmann, Matheus Augusto Eisenreich
Publikováno v:
Oral Presentations.
Background There is evidence that xanthine oxidase inhibitors (XOI) may reduce the risk of major adverse cardiovascular events (MACE) (1,2) and lower blood pressure (3). To date, this evidence is based mainly on observational studies (2). Objectives
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e7ed88d22d0983ab7045d1fd6a48d22a
https://doi.org/10.1136/annrheumdis-2017-eular.2674
https://doi.org/10.1136/annrheumdis-2017-eular.2674